Inactive Instrument

Enzymatica AB Stock Nasdaq Stockholm

SE0003943620

Analysts' recommendations: Enzymatica AB

24-07-19	Penser lowers motivated value for Enzymatica - raises required return to reflect risk	FW
24-04-26	Redeye lowers motivated value for Enzymatica to SEK 5.5 (6.0)	FW
24-02-20	Penser lowers Enzymaticas' motivated value	FW
23-11-08	Penser lowers motivated value for Enzymatica	FW
23-11-08	Redeye lowers motivated value for Enzymatica to SEK 6.0 (6.5)	FW

More recommendations

Managers and Directors: Enzymatica AB

Manager	Title	Age	Since
Sana Alajmovic CEO	Chief Executive Officer	-	2026-01-31
Ulf Thomas Blom COO	Chief Operating Officer	61	2010-12-31
Holger Lembrér DFI	Director of Finance/CFO	-	2026-04-12

Director	Title	Age	Since
Gudmundur Palmason CHM	Chairman	58	2016-02-14
Bengt Baron CHM	Chairman	64	2016-12-18
Mats K. Andersson BRD	Director/Board Member	71	2016-12-18

More insiders

Enzymatica AB (publ) is a Sweden-based life science company that develops and sells medical devices for infection-related diseases. The Company deals with research, development and sales of products based on enzyme technology and related activities. Enzymatica AB (publ) develops solutions that support the body's own defenses against virus, irritants and microorganisms. The Company offers products which are based on a barrier technology, includes marine enzymes. Enzymatica AB (publ) focuses on product development based on the tested and patented barrier technology used in the common cold product ColdZyme, a mouth spray that protects against colds, can help shorten the duration of the cold if used in the early stages of infection, relieves cold symptoms, and soothes sore throats.

Employees

Sector

Pharmaceuticals

Calendar

Earnings release - Q2 2026

More about the company

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

Market Cap	607M 532M 490M 459M 861M 57.24B 879M 5.89B 2.28B 28.29B 2.28B 2.23B 98.1B	P/E 2024	-5.73x	P/E 2025	-8.89x
Enterprise Value	575M 504M 464M 435M 815M 54.22B 832M 5.58B 2.16B 26.79B 2.16B 2.11B 92.91B	EV / Sales 2024	5.88x	EV / Sales 2025	7.96x
Free-Float	56.66%	Yield 2024 *	-	Yield 2025	-

06-24	Enzymatica AB Provides Update On The Evidence Base For Coldzyme And PLOS ONE Expression Of Concern Regarding Berlin II Article	CI
06-24	Scientific paper on Enzymatica's Berlin II study receives an Expression of Concern, update	FW
06-23	Study of Enzymatica's cold spray Coldzyme gets a warning flag	FW
06-09	Enzymatica AB Announces Appointment of Joakim Tingström Nordin as Nordic Marketing and Sales Director, Effective August 2026	CI
06-09	Enzymatica appoints new Head of Marketing and Sales to drive Coldzyme growth in the Nordics	FW
04-28	Enzymatica Q1 operating loss narrows to SEK 13.6 million	RE
04-28	Enzymatica narrows losses	FW
04-28	Enzymatica AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-01	Enzymatica Marketing Executive sells shares worth over SEK 0.1 million	FW
03-31	Enzymatica, Stada sign partnership agreement for Germany, Austria	RE
03-31	Enzymatica enters into agreement with Stada in Germany	FW
03-31	Enzymatica AB and Stada Arzneimittel Ag Sign Partnership Agreement for Launch and Distribution of Coldzyme Oral Spray Technology in Germany and Austria	CI
02-18	Enzymatica AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI

06-24	The evidence base for ColdZyme remains unchanged – PLOS ONE notice concerns the presentation of the Berlin II article, not the evidence base for ColdZyme	AQ
06-09	Enzymatica appoints Marketing and Sales Director to accelerate ColdZyme’s continued growth in the Nordics	AQ
06-08	Enzymatica : partners with Unibet Rose Rockets to put ColdZyme in the Giro d’Italia race routine	PU
05-07	Bulletin from annual general meeting of Enzymatica AB (publ) on 7 May 2026	AQ
04-28	Quarterly report Q1/2026 - Enzymatica strengthens international position through STADA agreement	AQ

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ENZYMATICA AB	+2.32%	+3.00%	-	-	62.47M
ELI LILLY AND COMPANY	+7.13%	+9.97%	+51.94%	+166.83%	1,077B
JOHNSON & JOHNSON	+3.99%	+11.50%	+67.53%	+55.63%	613B
ABBVIE INC.	+4.20%	+17.03%	+35.63%	+87.74%	448B
ROCHE HOLDING AG	+0.99%	+4.85%	+27.93%	+22.82%	332B
ASTRAZENECA PLC	+1.82%	+8.19%	+41.15%	+26.80%	293B
NOVARTIS AG	+0.22%	+6.75%	+31.51%	+42.02%	286B
NOVO NORDISK A/S	+0.73%	+8.53%	-26.22%	-40.85%	215B
AMGEN INC.	+1.56%	+6.14%	+28.38%	+59.45%	193B
GILEAD SCIENCES, INC.	+3.26%	+3.33%	+18.83%	+67.03%	159B
Average	+2.09%	+8.00%	+30.74%	+54.16%	401.79B
Weighted average by Cap.	+2.26%	+8.93%	+40.51%	+81.28%

	2024	2025
Net sales	45.58M 39.96M 36.83M 34.48M 64.66M 4.3B 66.01M 443M 171M 2.12B 171M 167M 7.37B	53.9M 47.26M 43.56M 40.79M 76.48M 5.08B 78.07M 524M 203M 2.51B 202M 198M 8.71B
Net income	-53.18M -46.63M -42.98M -40.24M -75.45M -5.02B -77.02M -517M -200M -2.48B -200M -195M -8.6B	-51.89M -45.5M -41.94M -39.26M -73.62M -4.89B -75.15M -504M -195M -2.42B -195M -191M -8.39B
Net Debt	-73.01M -64.02M -59.01M -55.24M -104M -6.89B -106M -709M -274M -3.4B -274M -268M -11.8B	-32.11M -28.15M -25.95M -24.3M -45.56M -3.03B -46.51M -312M -121M -1.5B -121M -118M -5.19B

Enzymatica AB Stock Nasdaq Stockholm

Stocks

SE0003943620

Pharmaceuticals

Valuation: Enzymatica AB

Latest news : Enzymatica AB

Analysts' recommendations: Enzymatica AB

Press Releases: Enzymatica AB

Quotes and Performance

Managers and Directors: Enzymatica AB

Other Pharmaceuticals

Financials

Company Profile